idasanutlin + cytarabine + daunorubicin

This drug is a **combination therapy** consisting of three agents: - **Idasanutlin**: a selective small-molecule antagonist of MDM2, designed to reactivate the p53 tumor suppressor pathway by preventing the interaction between MDM2 and p53, thereby promoting apoptosis in cancer cells. - **Cytarabine**: a nucleoside analog that inhibits DNA synthesis, primarily used as an antineoplastic agent for the treatment of acute myeloid leukemia (AML). - **Daunorubicin**: an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, blocking DNA replication and repair, and inducing cell death. The combination is primarily studied for the **induction treatment** of newly diagnosed, previously untreated acute myeloid leukemia (AML), and for maintenance therapy following remission. The regimen is typically administered intravenously with idasanutlin given first, followed by cytarabine, and then daunorubicin[1].